Editor’s Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach

Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population. To identify risk factors and mechanisms underlying t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Toxicol Sci
Prif Awduron: Mosedale, Merrie, Kim, Yunjung, Brock, William J., Roth, Sharin E., Wiltshire, Tim, Eaddy, J. Scott, Keele, Gregory R., Corty, Robert W., Xie, Yuying, Valdar, William, Watkins, Paul B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
Collaborative Cross and Tolvaptan-Induced Liver Injury
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075566/
https://ncbi.nlm.nih.gov/pubmed/28115652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw269
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg